A Phase 4 interventional study of Zoster Vaccine, Live and Comparator: placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 2nd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 4, and was the 6th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2007.
This study's enrollment of 11,999 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 3 in phase 4, and was the 9th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: vaccine
Biological: Zoster Vaccine, Live
Arm 2: Placebo Comparator
Biological: Comparator: placebo
single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
single 0.65 mL Placebo injection. 6 month treatment period.
Serious Adverse Events Reported Within 42 Days Postvaccination
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
Time frame: 42 Days
Serious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
Time frame: 6 months
Phase IV First subject enrolled on 17-Sep-2007. Last subject enrolled on 19-Jun-2008. The last subject's last visit was 15-Jan-2009. The study was conducted at 46 study centers throughout the United States, Canada, Germany, Spain, and United Kingdom.
| Milestone | ZOSTAVAX™ | Placebo |
|---|---|---|
| Started | 6000 | 5999 |
| Completed | 5913 | 5939 |
| Not completed | 87 | 60 |
| Withdrew: Death | 20 | 16 |
| Withdrew: Lost to follow-up | 45 | 30 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Withdrawal by subject | 17 | 10 |
| Withdrew: Screen failure | 1 | 0 |
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
| Participants | ZOSTAVAX™ | Placebo |
|---|---|---|
| Serious Adverse Events (AEs) | 84 | 67 |
| Serious AEs deemed vaccine-related by investigator | 2 | 0 |
| Death | 6 | 5 |
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.
| Participants | ZOSTAVAX™ | Placebo |
|---|---|---|
| Serious AEs | 340 | 300 |
| Serious AEs deemed vaccine-related by investigator | 2 | 1 |
| Death | 24 | 17 |
Collected over Serious AEs reported within 6 months (182 days) postvaccination. Only Serious adverse events were collected in this study. The "Other Adverse Events" table is not applicable for this study and shows "0/0" for " participants affected/at risk". Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOSTAVAX™ | — | 340/5,979 (5.7%) | — |
| Placebo | — | 300/5,990 (5%) | — |
| Event | ZOSTAVAX™ | Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 21/5979 | 14/5990 |
| Chest painGeneral disorders | 12/5979 | 17/5990 |
| PneumoniaInfections and infestations | 16/5979 | 13/5990 |
| Coronary artery diseaseCardiac disorders | 11/5979 | 15/5990 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 14/5979 | 10/5990 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 14/5979 | 8/5990 |
| Myocardial infarctionCardiac disorders | 8/5979 | 14/5990 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 12/5979 | 7/5990 |
| Renal failure acuteRenal and urinary disorders | 12/5979 | 2/5990 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 8/5979 | 11/5990 |
| Age, Continuous(years) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Mean | 70.5 ± 7.5 | 70.4 ± 7.6 | 70.5 ± 7.5 |
| Age, Customized(participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| 60 to 69 Years of Age | 3092 | 3113 | 6205 |
| 70 to 79 Years of Age | 1994 | 1986 | 3980 |
| ≥ 80 Years of Age | 897 | 898 | 1795 |
| Sex: Female, Male(Participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Female | 3515 | 3525 | 7040 |
| Male | 2468 | 2472 | 4940 |
| Race/Ethnicity, Customized(participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Black | 109 | 85 | 194 |
| White | 5759 | 5770 | 11529 |
| Other | 115 | 142 | 257 |
| Region(Participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| U.S. | 5309 | 5312 | 10621 |
| Non-U.S. | 674 | 685 | 1359 |
| Type of Residence(Participants) | ZOSTAVAX™ | Placebo | Total |
|---|---|---|---|
| Assisted Living | 176 | 162 | 338 |
| Independent Residential | 5790 | 5821 | 11611 |
| Nursing Home | 17 | 14 | 31 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Sep 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine